company background image
DBP B logo

Double Bond Pharmaceutical International NGM:DBP B Stock Report

Last Price

kr0.77

Market Cap

kr78.4m

7D

10.0%

1Y

-3.8%

Updated

27 Mar, 2024

Data

Company Financials

Double Bond Pharmaceutical International AB (publ)

NGM:DBP B Stock Report

Market Cap: kr78.4m

DBP B Stock Overview

Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases.

DBP B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Double Bond Pharmaceutical International AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Double Bond Pharmaceutical International
Historical stock prices
Current Share Pricekr0.77
52 Week Highkr2.00
52 Week Lowkr0.25
Beta0.68
1 Month Change9.40%
3 Month Change-4.00%
1 Year Change-3.76%
3 Year Change-63.25%
5 Year Change-86.71%
Change since IPO-82.93%

Recent News & Updates

Recent updates

Shareholder Returns

DBP BSE PharmaceuticalsSE Market
7D10.0%3.0%1.9%
1Y-3.8%81.6%17.1%

Return vs Industry: DBP B underperformed the Swedish Pharmaceuticals industry which returned 85.9% over the past year.

Return vs Market: DBP B underperformed the Swedish Market which returned 19% over the past year.

Price Volatility

Is DBP B's price volatile compared to industry and market?
DBP B volatility
DBP B Average Weekly Movement15.4%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement6.1%
10% most volatile stocks in SE Market12.9%
10% least volatile stocks in SE Market3.4%

Stable Share Price: DBP B's share price has been volatile over the past 3 months.

Volatility Over Time: DBP B's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
201410Igor Lokothttps://www.doublebp.com

Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases. It offers Temodex, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia.

Double Bond Pharmaceutical International AB (publ) Fundamentals Summary

How do Double Bond Pharmaceutical International's earnings and revenue compare to its market cap?
DBP B fundamental statistics
Market capkr78.36m
Earnings (TTM)-kr17.34m
Revenue (TTM)kr1.37m

57.2x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DBP B income statement (TTM)
Revenuekr1.37m
Cost of Revenuekr4.68m
Gross Profit-kr3.31m
Other Expenseskr14.03m
Earnings-kr17.34m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin-241.22%
Net Profit Margin-1,265.24%
Debt/Equity Ratio0%

How did DBP B perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.